A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in ...